| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;100:61-66.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Impact of Prophylactic Immediate Posttransplant Ganciclovir on Development of Transplant Atherosclerosis
A Post Hoc Analysis of a Randomized, Placebo-Controlled Study
From Stanford University School of Medicine (H.A.V., S.-Z.G., S.A.H., P.O., E.B.S., B.W.B., T.C.M., J.S.S.), Stanford, Calif, and University of Utah Medical Center (S.G.M., D.G.R.), Salt Lake City, Utah.
Background—Coronary artery disease occurs in an accelerated fashion in the donor heart after heart transplantation (TxCAD), but the cause is poorly understood. The risk of developing TxCAD is increased by cytomegalovirus (CMV) infection and decreased by use of calcium blockers. Our group observed that prophylactic administration of ganciclovir early after heart transplantation inhibited CMV illness, and we now propose to determine whether this therapy also prevents TxCAD.
Methods and Results—One hundred forty-nine consecutive patients (131 men and 18 women aged 48±13 years) were randomized to receive either ganciclovir or placebo during the initial 28 days after heart transplantation. Immunosuppression consisted of muromonab-CD3 (OKT-3) prophylaxis and maintenance with cyclosporine, prednisone, and azathioprine. Mean follow-up time was 4.7±1.3 years. In a post hoc analysis of this trial designed to assess efficacy of ganciclovir for prevention of CMV disease, we compared the actuarial incidence of TxCAD, defined by annual angiography as the presence of any stenosis. Because calcium blockers have been shown to prevent TxCAD, we analyzed the results by stratifying patients according to use of calcium blockers. TxCAD could not be evaluated in 28 patients because of early death or limited follow-up. Among the evaluable patients, actuarial incidence of TxCAD at follow-up (mean, 4.7 years) in ganciclovir-treated patients (n=62) compared with placebo (n=59) was 43±8% versus 60±10% (P<0.1). By Cox multivariate analysis, independent predictors of TxCAD were donor age >40 years (relative risk, 2.7; CI, 1.3 to 5.5; P<0.01) and no ganciclovir (relative risk, 2.1; CI, 1.1 to 5.3; P=0.04). Stratification on the basis of calcium blocker use revealed differences in TxCAD incidence when ganciclovir and placebo were compared: no calcium blockers (n=53), 32±11% (n=28) for ganciclovir versus 62±16% (n=25) for placebo (P<0.03); calcium blockers (n=68), 50±14% (n=33) for ganciclovir versus 45±12% (n=35) for placebo (P=NS).
Conclusions—TxCAD incidence appears to be lower in patients treated with ganciclovir who are not treated with calcium blockers. Given the limitations imposed by post hoc analysis, a randomized clinical trial is required to address this issue.
Key Words: cytomegalovirus • ganciclovir • atherosclerosis • transplantation
This article has been cited by other articles:
 |
|
 |
|
  J. D. Walker, C. L. Maier, and J. S. Pober Cytomegalovirus-Infected Human Endothelial Cells Can Stimulate Allogeneic CD4+ Memory T Cells by Releasing Antigenic Exosomes J. Immunol., February 1, 2009; 182(3): 1548 - 1559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Limaye, K. A. Kirby, G. D. Rubenfeld, W. M. Leisenring, E. M. Bulger, M. J. Neff, N. S. Gibran, M.-L. Huang, T. K. Santo Hayes, L. Corey, et al. Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients JAMA, July 23, 2008; 300(4): 413 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dumortier, D. N. Streblow, A. V. Moses, J. M. Jacobs, C. N. Kreklywich, D. Camp, R. D. Smith, S. L. Orloff, and J. A. Nelson Human Cytomegalovirus Secretome Contains Factors That Induce Angiogenesis and Wound Healing J. Virol., July 1, 2008; 82(13): 6524 - 6535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Bolovan-Fritts and S. A. Spector Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction Blood, January 1, 2008; 111(1): 175 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Fishman Infection in Solid-Organ Transplant Recipients N. Engl. J. Med., December 20, 2007; 357(25): 2601 - 2614. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Bolovan-Fritts, R. N. Trout, and S. A. Spector High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage Blood, September 15, 2007; 110(6): 1857 - 1863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Potena, C. T. J. Holweg, M. L. Vana, L. Bashyam, J. Rajamani, A. L. McCormick, J. P. Cooke, H. A. Valantine, and E. S. Mocarski Frequent Occult Infection with Cytomegalovirus in Cardiac Transplant Recipients despite Antiviral Prophylaxis J. Clin. Microbiol., June 1, 2007; 45(6): 1804 - 1810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Webber Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in Children Circulation, April 3, 2007; 115(13): 1701 - 1702. [Full Text] [PDF]
|
|
|
|
|
|
R.-E. W. Kavey, V. Allada, S. R. Daniels, L. L. Hayman, B. W. McCrindle, J. W. Newburger, R. S. Parekh, and J. Steinberger Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics Circulation, December 12, 2006; 114(24): 2710 - 2738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tellides Th1 Adaptive Immune Responses in Cardiac Graft Arteriosclerosis: Deleterious or Beneficial? Circulation, October 10, 2006; 114(15): 1561 - 1564. [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Kalil, J. Levitsky, E. Lyden, J. Stoner, and A. G. Freifeld Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients Ann Intern Med, December 20, 2005; 143(12): 870 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Uknis Prophylaxis of cytomegalovirus disease in transplant patients Am. J. Health Syst. Pharm., April 15, 2005; 62(suppl_1): S3 - S6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. J. Kuypers, K. Claes, P. Evenepoel, B. Maes, and Y. Vanrenterghem A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients J. Antimicrob. Chemother., March 1, 2005; 55(3): 391 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Bolovan-Fritts, R. N. Trout, and S. A. Spector Human Cytomegalovirus-Specific CD4+-T-Cell Cytokine Response Induces Fractalkine in Endothelial Cells J. Virol., December 1, 2004; 78(23): 13173 - 13181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Petrakopoulou, M. Kubrich, S. Pehlivanli, B. Meiser, B. Reichart, W. von Scheidt, and M. Weis Cytomegalovirus Infection in Heart Transplant Recipients Is Associated With Impaired Endothelial Function Circulation, September 14, 2004; 110(11_suppl_1): II-207 - II-212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Weis, T. N. Kledal, K. Y. Lin, S. N. Panchal, S. Z. Gao, H. A. Valantine, E. S. Mocarski, and J. P. Cooke Cytomegalovirus Infection Impairs the Nitric Oxide Synthase Pathway: Role of Asymmetric Dimethylarginine in Transplant Arteriosclerosis Circulation, February 3, 2004; 109(4): 500 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Potena, G. Frascaroli, F. Grigioni, T. Lazzarotto, G. Magnani, L. Tomasi, F. Coccolo, L. Gabrielli, C. Magelli, M. P. Landini, et al. Hydroxymethyl-Glutaryl Coenzyme A Reductase Inhibition Limits Cytomegalovirus Infection in Human Endothelial Cells Circulation, February 3, 2004; 109(4): 532 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hadaya, W. Wunderli, C. Deffernez, P.-Y. Martin, G. Mentha, I. Binet, L. Perrin, and L. Kaiser Monitoring of Cytomegalovirus Infection in Solid-Organ Transplant Recipients by an Ultrasensitive Plasma PCR Assay J. Clin. Microbiol., August 1, 2003; 41(8): 3757 - 3764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vassalli, A. Gallino, M. Weis, W. von Scheidt, L. Kappenberger, L.K. von Segesser, J.-J. Goy, and on behalf of the Working Group Microcirculation of Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy Eur. Heart J., July 1, 2003; 24(13): 1180 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Weis and J. P. Cooke Cardiac Allograft Vasculopathy and Dysregulation of the NO Synthase Pathway Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 567 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Streblow, C. Kreklywich, Q. Yin, V. T. De La Melena, C. L. Corless, P. A. Smith, C. Brakebill, J. W. Cook, C. Vink, C. A. Bruggeman, et al. Cytomegalovirus-Mediated Upregulation of Chemokine Expression Correlates with the Acceleration of Chronic Rejection in Rat Heart Transplants J. Virol., February 1, 2003; 77(3): 2182 - 2194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Suzuki, B. Murtuza, N. Suzuki, M. Khan, Y. Kaneda, and M. H. Yacoub Human Cytomegalovirus Immediate-Early Protein IE2-86, but not IE1-72, Causes Graft Coronary Arteriopathy in the Transplanted Rat Heart Circulation, September 24, 2002; 106(12_suppl_1): I-158 - I-162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Yen, G. Pilkington, R. C. Starling, N. B. Ratliff, P. M. McCarthy, J. B. Young, G. M. Chisolm, and M. S. Penn Increased Tissue Factor Expression Predicts Development of Cardiac Allograft Vasculopathy Circulation, September 10, 2002; 106(11): 1379 - 1383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Griffiths The treatment of cytomegalovirus infection J. Antimicrob. Chemother., February 1, 2002; 49(2): 243 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. TIKKANEN, E. A. KALLIO, C. A. BRUGGEMAN, P. K. KOSKINEN, and K. B. LEMSTROM Prevention of Cytomegalovirus Infection-enhanced Experimental Obliterative Bronchiolitis by Antiviral Prophylaxis or Immunosuppression in Rat Tracheal Allografts Am. J. Respir. Crit. Care Med., August 15, 2001; 164(4): 672 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Pescovitz, J. Rabkin, R. M. Merion, C. V. Paya, J. Pirsch, R. B. Freeman, J. O'Grady, C. Robinson, Z. To, K. Wren, et al. Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2811 - 2815. [Abstract] [Full Text]
|
|